KODIAK SCIENCES INC (KOD)
Health Care · NASDAQ
Kodiak Sciences is a pre-commercial retina biotech pioneering ultra-long-acting intravitreal biologics via its ABC platform, with lead anti-VEGF Zenkuda completing four Phase 3 studies and ready for 2026 BLA filings in diabetic retinopathy, RVO, and wet AMD.
What KODIAK SCIENCES INC does
Kodiak Sciences is a precommercial retina-focused biotechnology company developing next-generation intravitreal biologic therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company's lead program, Zenkuda (tarcocimab), is an anti-VEGF therapy with a 20-day ocular half-life designed for flexible dosing in retinal vascular diseases, and has completed four Phase 3 studies in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The company is also advancing KSI-501 (anti-IL-6/VEGF-trap bispecific) and KSI-101 (anti-IL-6/VEGF bispecific) in Phase 3 trials, along with pipeline programs in ocular inflammation and other retinal indications.
Themes: ["Retinal vascular disease / anti-VEGF therapy","Diabetic retinopathy","Retinal vein occlusion (RVO)","Wet age-related macular degeneration (wet AMD)","Extended durability biologics / intravitreal dosing","Bispecific antibodies","Ocular inflammation","AI-enabled medical imaging / VETi wearable technology"]
Fundamentals
- Price$40.08 as of 2026-07-09 close
- Market cap$2.5B as of 2026-07-10
- 1-year return+802.7% as of 2026-07-09 close
- ROE-253.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.19 as of 2026-07-10
Key risks (from latest filing)
["Zenkuda and other clinical programs have not yet received regulatory approval; regulatory submissions planned for 2026 carry approval risk and timing uncertainty.","Competition from established anti-VEGF therapies (aflibercept, bevacizumab, ranibizumab) and other emerging retinal therapies could limit market adoption and pricing power.","Manufacturing scale-up and commercial supply chain dependencies with Lonza could impact launch timelines and cost of goods."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.